TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium - Related Studies

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

This study has been completed.

Study NCT00077688. Last updated on October 4, 2007. Information provided by OncoGenex Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Neoplasms
		Ureteral Neoplasms
		Urethral Neoplasms
		Carcinoma, Transitional Cell

2	Additional conditions recognized in this trial
		Carcinoma
		Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Ureteral Diseases
		Urethral Diseases
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		TOCOSOL Paclitaxel

5	Additional drug interventions recognized in this trial
		Paclitaxel

6	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		Sonus Pharmaceuticals